Sign in
CompletedPhase 2/3

Ultrasound-Guided Stellate Ganglion Block in Fibromyalgia

Key facts

Who runs it
Sanliurfa Education and Research Hospital
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2/3
People taking part
68 people enrolled
Started
1 Jun 2025
Ended
25 Dec 2025
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Lidocaine and Dexamethasone
  • Normal Saline
Record updated
16 January 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Diagnosis of Fibromyalgia Syndrome (FMS) according to the 2016 American College of Rheumatology criteria
  • Followed for at least 1 year with insufficient benefit from previous pharmacological and/or non-pharmacological treatments
  • Receiving a stable dose of duloxetine 60 mg once daily for at least 4 weeks prior to inclusion
  • Willingness to continue the fixed dose of duloxetine throughout the study
  • Aged between 18 and 65 years

Who cannot take part

  • Non-pharmacological treatments within the previous 6 months (e.g., acupuncture, ozone therapy, cognitive behavioral therapy)
  • Local infection at the injection site
  • Known allergy to local anesthetics
  • History of malignancy
  • Bleeding or coagulation disorders or use of oral anticoagulants
  • Uncontrolled hypertension, diabetes mellitus, asthma, chronic obstructive pulmonary disease, or heart failure
  • Psychiatric or cognitive disorders that could interfere with treatment compliance (e.g., severe psychiatric illness, dementia)
  • Pregnancy or suspected pregnancy
  • Refusal of interventional treatment

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study evaluates the efficacy and safety of ultrasound-guided stellate ganglion block (SGB) as an adjunctive treatment for patients with treatment-resistant fibromyalgia. Patients who continue to experience significant symptoms despite stable duloxetine therapy (60 mg/day) were randomized to receive either ultrasound-guided SGB or a sham control procedure. The study aims to determine if SGB can provide clinically meaningful improvements in fibromyalgia impact and pain intensity compared to a sham injection.

The 2 groups in the trial

  • Stellate Ganglion BlockTreatment being tested

    Participants in this group received two ultrasound-guided stellate ganglion blocks at the C7 level, performed one week apart. Under real-time ultrasound guidance, a 22-gauge spinal needle was advanced to the stellate ganglion region. Following negative aspiration, a 7 mL mixture containing 8 mg of non-particulate dexamethasone and 2 mL of 2% lidocaine (diluted with normal saline) was injected. Success was clinically confirmed by the development of ipsilateral Horner syndrome.

    Treatment: Lidocaine and Dexamethasone

  • Sham ControlSham treatment, for comparison

    Participants in this group underwent the same preparation, positioning, and ultrasound imaging as the intervention group to maintain blinding. They received two sham procedures, performed one week apart. In each procedure, 2 mL of normal saline was injected intramuscularly into the sternocleidomastoid muscle in a region distant from the stellate ganglion. This procedure replicated the needle insertion and ultrasound application without affecting the sympathetic nerves.

    Treatment: Normal Saline

Results explained

A paper that names this trial, explained in plain words.

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Ultrasound-Guided Stellate Ganglion Block in Fibromyalgia: A Randomized, Single-Center, Single-Blind, Sham-Controlled Trial
Publications
Record updated
16 January 2026